LP
TVTX icon

LMR Partners’s Travere Therapeutics TVTX Stock Holding History

LMR Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,220
Closed -$36.2K – 1782
2026
Q1 		$36.2K Buy
+1,220
New +$36.5K ﹤0.01% 1326
2021
Q1 		– Sell
-33,000
Closed -$899K – 1058
2020
Q4 		$899K Buy
+33,000
New +$770K 0.01% 295
2015
Q2 		– Sell
-11,997
Closed -$287K – 604
2015
Q1 		$287K Buy
+11,997
New +$183K 0.04% 345

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's TVTX Position: Q2 2026 in Review

LMR Partners sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 1,220 shares — an estimated $36.2K sold.

LMR Partners first reported a position in TVTX in Q1 2015 and held it in 3 quarters. The position peaked at $899K in Q4 2020. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • LMR Partners reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • LMR Partners sold 1,220 Travere Therapeutics shares in Q2 2026, an estimated $36.2K.
  • LMR Partners first reported a position in Travere Therapeutics in Q1 2015 and held it in 3 quarters.
  • LMR Partners's Travere Therapeutics position peaked at $899K in Q4 2020.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.